Mar. 23 at 1:14 PM
$MLTX FWIW I was a long time holder in
$ARIA . Goldman Sachs also had nothing good to say about them too:
Goldman Sachs' Stance on ARIA
Sell Rating (2013): Following the FDA's suspension of Iclusig sales in October 2013 due to life-threatening blood clots, Goldman Sachs was among the prominent firms that maintained a Sell or highly cautious rating.
Price Target Cuts: Analysts at the firm slashed price targets significantly during the safety crisis, reflecting concerns that the drug's "black box" warning and restricted label would permanently impair its multi-billion dollar "blockbuster" potential.
Scepticism on Recovery: Even as the FDA allowed Iclusig back on the market in early 2014, Goldman remained skeptical about the company's ability to regain its previous valuation, citing the intense competition from Novartis and Bristol-Myers Squibb in the leukemia space.
M&A Perspective: By the time of the 2017 acquisition by Takeda, Goldman's consensus was that Ariad was a "single-product
